Investors calmer after Oncolytics explains split of Phase III Reolysin trial
This article was originally published in Scrip
Executive Summary
Oncolytics Biotech saw its US stock price fall by as much as 25.5% on 12 September when the Canadian developer of oncolytic viruses for the treatment of cancer announced that it would double the number of patients enrolled in its Phase III clinical trial for intravenous Reolysin in combination with carboplatin and paclitaxel for the treatment of head and neck cancers.
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).